Clinical Trial Update: VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating VTX958 for moderately to severely active Crohn's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• VTX958

Snippet

Sponsor: Ventyx Biosciences, Inc | Conditions: Crohn Disease | Phase 2 | Status: TERMINATED